The GLP-1 Masterclass

in Customer Consciousness.

What the Most Consequential Category Event in a Generation Teaches Us About Commercial Strategy, Resource Allocation, and Unlocking the Next Generation of Growth.

Wayne Simmons, CCXP

Founder and Commercial Systems Architect

CEA PRACTICE PAPER NO. 3 · JULY 2026

CEA PRACTICE PAPER NO. 3

About This Practice Paper

What the most consequential category event in a generation teaches us about commercial strategy, resource allocation, and unlocking the next generation of growth.

This paper begins from a conviction that shapes everything this practice builds: **the future of pharma commercial is more experiential than promotional.** Promotional and clinical acumen remain essential, and the organizations that have built them hold real assets. What is changing is where durable advantage now accumulates. It is moving toward the quality of the system surrounding the therapy, toward whether a patient can begin, persist, and realize the value the science promised, and toward whether a healthcare professional finds the enterprise coherent to work with across everything it brings them. Promotional excellence wins the moment. Experiential prowess wins the journey, and increasingly the category.

A second conviction follows directly from the first. **HCPs and patients arrive with consumer-grade expectations.** Those expectations are formed everywhere else in their lives, by the products and services that recognize them, remember them, and make the next step obvious. People do not suspend that standard when they cross into a clinical setting. They bring it with them, and they apply it, whether or not the organization on the other side has designed for it. Meeting that standard is not a matter of polish. It determines whether intent progresses into outcome.

Held together, these two truths create a requirement worth naming plainly. Experiential design is downstream of customer understanding. An enterprise cannot build consumer-grade systems for people whose world it has not read, because the design brief lives in that world rather than in the product. This is why the practice invests so heavily in customer consciousness: the deep search, disciplined examination, and organizational internalization of customer context. Context is the raw material of experience design, and it is also, as this paper argues, the raw material of category formation itself.

This is the work The Customer Excellence Agency does. CEA helps global pharmaceutical companies build the **predisposition to unlock customer and experience-led growth**: the standing capacity to read customer context before a market forms, to architect consumer-grade commercial systems around what that reading finds, and to govern whether the value the science promises is actually realized in a customer's life. Predisposition is the operative word. Most organizations can mount the effort once, under a committed leader, for a single brand. Far fewer are built so that reading context and designing for it is simply how the commercial organization behaves, on a cadence, across a portfolio, after that leader has moved on.

CEA Practice Papers set out the working doctrine behind that work. Each makes one argument, carries one instrument a leader can apply without a consultant in the room, and is written to be argued with, not

admired. They are published for commercial leaders accountable for growth and for the investors who underwrite it.

What you will take from this paper

You Will Leave With	What It Gives You
A reading of why GLP-1 formed	An account of the human conditions that made the category inevitable years before it declared itself, drawn from customer context, not from clinical mechanism or market size. This is the lesson the paper argues transfers.
The Convergence Readiness Model™	A seven-condition diagnostic for assessing whether a human condition is approaching category formation, and where it currently sits. Applicable to any therapeutic adjacency or investment opportunity under consideration. The scored version, with behavioral anchors for each dimension, is published separately as a companion working tool.
The Replication Protocol	Five practices in sequence that convert lived human experience into a category thesis. The paper runs the protocol end to end on a worked example so the technique is demonstrated, not described.
An allocation logic	A method for converting a diagnostic read into a capital decision, with a defined posture, instrument set, and return mechanism for each position on the output grid.
A structural argument	The case for Customer Excellence as the Fourth Pillar of commercial excellence, and a view of what it owns upstream in portfolio, midstream in architecture, and downstream in value realization.

The intent is practical. A commercial leader should be able to run the protocol against their own portfolio using nothing beyond this document, and to arrive at a defensible position on two or three conditions where their organization already holds the relationships, credibility, or infrastructure to lead.

Where this sits in the body of work

This paper belongs to a developing collection that examines the same conviction at different altitudes of the commercial system. **The Pharma Front Door** examines the contact layer, and argues for an enterprise capability that meets HCPs and patients as one relationship across a set of brand-organized encounters. **Closing Pharma's Intent-to-Impact Gap** examines value realization, and instruments the distance between what the enterprise intends and what the customer actually experiences. This paper examines the question furthest upstream: where categories come from, and how an organization learns to read the human context that creates them. Read together, the three describe one commercial model: outside-in rather than product-out, experiential as well as promotional, and organized around the customer's path to realized value. Each stands alone, and each is more useful alongside the others.

Executive Summary

GLP-1 is one of the most powerful forces to move pharma, healthcare markets, and broader society in a generation. It is reshaping valuations, restructuring employer benefits, intensifying payer debates, redefining what primary care conversations look like, expanding the cultural boundaries of what medicine is expected to address, and changing what millions of people believe is possible for their own health and their own bodies. The dominant conversation in pharma boardrooms and C-suites right now is a version of the same question: how do we get into this market?

That is the right question to ask. It is not, however, the more interesting one. The more interesting question is what comes after GLP-1. Not which mechanism follows semaglutide or tirzepatide in the obesity pipeline, but which human conditions are accumulating the same forces that made GLP-1 inevitable: persistent burden, normalized underservice, emotional intensity, cultural readiness, scientific unlock, and a deep demand for agency over a life condition that has felt intractable. That question is worth more than any single category entry, and it is the question that customer consciousness is built to answer.

This paper argues that GLP-1 is more than a category story. It is a customer consciousness masterclass. Every condition that made it inevitable, every force that accelerated its adoption, and every dynamic now intensifying competition within it contains a lesson that customer-conscious companies can extract, systematize, and apply forward. The companies that do that work will not be chasing the next GLP-1. They will be creating it.

The word masterclass is chosen precisely, because a masterclass is taught by someone who did the thing well. Novo Nordisk and Eli Lilly both read the human context of obesity correctly, and both built the clinical credibility, prescribing confidence, and commercial architecture that turned an intervention into a category. Semaglutide and tirzepatide arrived from two organizations working the same condition with the same seriousness, and each moved the market in ways the other could not have moved it alone. None of the underlying evidence was hidden. The prevalence was documented, the failed interventions catalogued, the workaround spending visible on every retail shelf, and the cultural reframing of obesity from moral failure to metabolic condition underway in public for years. The reading was available to anyone looking, and two companies looked.

What follows from that demonstration is the harder observation, and it is not an indictment of anyone. Reading one condition correctly proves the reading is possible. It does not make it repeatable. In the commercial organizations I have worked inside and audited, no function has carried the remit of reading customer context ahead of category formation: no standing brief to detect human conditions accumulating toward a market, no cadence on which that detection runs, and no instrument carrying its output into portfolio strategy. Reading one condition well produces a franchise. Reading any condition well produces a capability, and those are different assets with different half-lives.

The consequence shows up in how the industry explains its own largest events. Category formation gets treated as weather. Something arrives, the science aligns with the moment, and a market appears where none existed. That account is comfortable and it is wrong. Categories have an anatomy. The

forces that produced obesity were present, legible, and enumerable years before the unlock, and equivalent forces are present, legible, and enumerable in other conditions today. **Massive markets in pharma do not have to be bolts of lightning.** There is a science to reading where they form, and this paper sets that science out as a repeatable discipline, not a fortunate instinct.

Capital markets call GLP-1 a supercycle. That reading is accurate and almost entirely uninteresting, because it measures the wave without explaining the water. A supercycle is not a demand creation event. It is a demand release event, and what releases is customer context that has been accumulating, unread, for decades. Analysts can size a supercycle. They cannot explain why supercycles form, why this human condition and not another, or why the wave broke in 2021 rather than 2011 when the burden was identical and the prevalence was already documented. Those are questions about customers, and they are answerable, which is precisely what the winners demonstrated.

The discipline that answers them has a name. **Customer consciousness** is the practice of reading a customer's world deeply enough that what their life is making them need becomes visible before any market has formed around it. Section 3 sets out what that involves and where most organizations stop short. GLP-1 is the clearest demonstration of it available.

The argument of this paper is that customer context is a first principle of commercial strategy, not an input to commercial execution. It is as irreducible to the commercial enterprise as mechanism is to the scientific one. Pharma reasons from first principles in the laboratory and has largely reasoned by analogy in the marketplace, taking the last launch as the template for the next. The obesity category was won by an approach closer to the first habit than the second: read the condition people were actually living with, then build the system that would let a credible answer land. That sequence is repeatable, and repeating it deliberately is worth considerably more than entering the category it produced.

The structural answer is not another program. It is a fourth pillar. Pharma commercial excellence was built on three: launch excellence, marketing excellence, and sales excellence. Each is necessary, each has professionalized over decades, and each shares one boundary condition that four decades of refinement never removed. All three optimize performance within categories that already exist. **Customer Excellence** is the Fourth Pillar, the enterprise discipline that institutionalizes customer context as a first principle, senses categories before they form, architects consumer-grade commercial systems around them, and governs whether customers realize the value the science promises.

GLP-1 is the masterclass. Customer consciousness is the discipline. The Convergence Readiness Model is the instrument. The Fourth Pillar is the institution. The companies that build it will not be chasing the next GLP-1. They will be creating it.

Key Findings

1	**GLP-1 did not create a customer need. It unlocked one that had been building for decades, and the companies that read it won.** *Persistent burden, normalized by clinical underservice and cultural stigma, created latent demand the science released instead of generating. The category was inevitable. Most pharma strategy treated it as surprising. That gap between inevitability and surprise is the strategic problem customer consciousness is built to close.*
2	**The need was never weight loss. It was agency, and customers seeking agency behave as consumers.** *Patients self-recognized, self-funded, formed communities, and bypassed clinical infrastructure. High-agency conditions are consumer-grade markets and demand consumer-grade commercial architecture.*
3	**Customer context is a first principle of commercial strategy, not an input to execution.** *Two companies proved the read was available. Neither the industry nor its commercial model turned that into a standing capability, which is why the next convergence will be found by whoever happens to be looking closely at the right condition, unless the looking is made systematic.*
4	**The Convergence Readiness Model identifies where the next category is forming, before it declares itself.** *Seven conditions: persistent need, normalized burden, identity intensity, cultural readiness, self-recognition, scientific unlock, and ecosystem potential. Nine conditions already show strong convergence.*
5	**A supercycle is not demand creation. It is context debt discharging, and consumers have paid the interest.** *Context debt is the liability carried for context an organization encountered but never internalized. Where value leakage measures what an enterprise loses inside a category it already competes in, context debt measures what it never collects because it never read the context that would have created the category. Its proof is behavioral, not financial.*
6	**Experience architecture is now the primary source of defensible advantage, and the Fourth Pillar builds it.** *Molecule differentiation is narrowing. The three incumbent pillars optimize within categories. Customer Excellence reads the contexts that create them and governs value realization inside them.*

SECTION 1

The Category Formed Where Context Was Already Present

Walk into any pharma C-suite today and you will find a version of the same conversation. The last comparable events were the statin era of the 1990s, when Lipitor and its competitors redefined cardiovascular risk management and created a new paradigm for preventive medicine, and the launch of Viagra in 1998, which demonstrated what happens when a clinically consequential, personally legible, and culturally loaded condition finally meets a credible intervention patients feel socially permitted to seek. GLP-1 combines the population-scale preventive logic of the first with the identity and cultural unlock dynamics of the second, and it has surpassed both in the speed and breadth of its societal impact. The question dominating strategic planning cycles, investment committees, and commercial leadership agendas is predictable and entirely rational: how do we get into this market?

It is a reasonable question, and answering it well requires first being precise about what happened here, because the common telling is imprecise in a way that matters commercially. The industry did not collectively miss obesity. Two companies read it and were paid for reading it, and understanding exactly what they read is the difference between admiring the outcome and being able to reproduce it.

What Novo Nordisk and Lilly understood was not that obesity was prevalent, which everyone knew, or that a mechanism existed, which the science was making plain. Both understood what the condition had done to the people living inside it. Decades of effort, relapse, and self-blame had produced a population that had stopped expecting help and had internalized the failure as personal. A company reading prevalence data sees a large market poorly served. A company reading that condition sees something different: an enormous population primed to move the moment something credible arrived, and a permission structure that would collapse in months once the first patients started telling each other it worked. The commercial architectures built around semaglutide and tirzepatide reflect the second reading, not the first, which is why the category formed at the speed it did.

That two organizations arrived at the same read independently matters, because it rules out luck. One company reading one condition correctly is an anecdote. Two companies competing on the same customer understanding, each building a distinct architecture around it, is evidence that the understanding was there to be had by anyone prepared to look.

What made that reading available is that none of the evidence was hidden. The condition affected hundreds of millions of people. The failure of existing interventions was clinically established and personally lived. Consumers were spending tens of billions of dollars annually on weight management workarounds. The cultural reframing of obesity from moral failure to metabolic condition was underway in public discourse for years before the science matured. Every signal was legible to anyone whose attention was on customer context. Two companies read it, which is a far more useful fact than any post-mortem, because it demonstrates that the reading is possible, not simply desirable.

The strategic error is not in the past. It is being made now. The numbers describe a category that has finished forming and started maturing. IQVIA estimates the global obesity medicines market reached $66 billion in list-price sales in 2025 and could rise to $92 billion in 2026. The World Health Organization issued its first global guideline on GLP-1 medicines for obesity in December 2025. AstraZeneca, Pfizer, Roche, Amgen, and Structure Therapeutics are among the companies advancing GLP-1 and adjacent metabolic mechanisms, oral formulations are progressing across multiple programs, and differentiation has moved from whether the therapy works to how much weight loss, how tolerable, how convenient, covered or cash-pay. That is a commodity market in formation, and the assets that matter in it have already been bought by someone else at pre-declaration prices.

There is a second lesson inside the same event, and it belongs to the experience layer instead of the molecule. Hims and Hers, Ro, and Amazon captured meaningful positions in the GLP-1 category without discovering, developing, or manufacturing anything. They entered through onboarding, access, affordability, and continuity, which is where patients actually experience the therapy. Compounded alternatives reshaped access patterns before regulators moved to restrict them. Payers began recalibrating, with Cigna announcing in 2026 that it would discontinue GLP-1 obesity coverage for its own employees while maintaining diabetes-related coverage. In a formed category, advantage migrates to whoever designed for the customer's experience of value realization. That is a second discipline, and this paper treats it as the midstream altitude of the same capability.

Answering it requires accepting that the obesity reading, however well executed, was an instance and not a system. No mechanism inside the industry converts that success into a standing capability. There is no function whose brief is to scan human conditions for convergence, no cadence on which that scan is run, and no instrument that carries its output into portfolio strategy. Which means the next convergence will be found the same way this one was, by a company with a particular reason to look closely at a particular condition, rather than by an organization that looks at all of them as a matter of course. That is a serviceable way to win once. It is not a way to keep winning.

> ***Massive markets in pharma do not have to be bolts of lightning. Obesity proved the reading is possible. What almost nobody has built is the organ that makes it repeatable, and the difference between those two things is the difference between a franchise and a method.***

◆ PRACTICE PRISM *Seeing the same reality through a different lens*

CONVENTIONAL LENS

The most important GLP-1 strategic question is: how do we enter this category and capture share before the window closes?

▶️ THROUGH THE PRACTICE PRISM

The most important GLP-1 strategic question is: what did this category reveal about the human conditions that make markets inevitable, and where is that pattern already forming again?

SECTION 2

Customer Context as a First Principle

Pharma is, at its scientific core, a first-principles industry. Drug discovery does not reason by analogy. It reasons from mechanism: the biology of the target, the chemistry of the intervention, the causal pathway from molecule to outcome. Nobody advances an asset because a similar asset worked in an adjacent indication; the science demands a causal account. Yet the same industry has spent decades running its commercial enterprise almost entirely by analogy. The last launch becomes the template for the next one. The benchmark defines the ambition. The segmentation archetype and the omnichannel playbook are inherited, refined, and redeployed. Commercial strategy in pharma has largely been an exercise in pattern replication. The obesity category is what it looks like when a company breaks that habit and reasons instead from the condition itself.

A first principle is a proposition that cannot be decomposed further and from which everything else in a system must be derived. In pharma's scientific enterprise, mechanism, efficacy, and safety hold that status. The commercial enterprise has an equivalent that has never been formally granted the standing it already holds in reality: the customer in context. Not the customer as a segment, a decile, a persona, or a journey stage. The customer as a person living inside a world of burden, aspiration, identity, social experience, economic constraint, and cultural moment. Every commercial construct the industry optimizes is derivative of that world. Segments are abstractions of it. Journeys are traces through it. Channels are routes into it. Messages are bids for meaning within it. When the derivative constructs are optimized while the underlying context goes unread, the result is exactly what GLP-1 exposed: exquisite execution inside categories, structural blindness to the conditions that create them.

Treating customer context as a first principle changes the order of commercial reasoning. The conventional sequence starts with the asset and works outward: indication, positioning, segmentation, targeting, channel plan. The first-principles sequence starts with the context and works inward: what world is this person living in, what burden have they normalized, what agency are they seeking, what would they accept as a credible answer, and only then, what must the commercial system be for the value of the science to be realized in that world. The first sequence produces launches. The second produces categories, which is what Novo Nordisk and Lilly demonstrated at a scale that is difficult to argue with.

What the Fast-Follower Misses

The distinction between the two sequences is easiest to see in what a fast-follower looks at. It sees disease prevalence, mechanism validation, addressable market, and pipeline gap. Those four things are visible from outside the customer's world, they can be assembled from purchased data, and none of them explains why the category formed when it did. What the fast-follower does not see is the customer condition that made the category inevitable in the first place: the decades of failed interventions, the normalized burden, the accumulated frustration, the identity-level consequences, and the cultural moment that turned latent demand into release. That condition is not in the data set. It is in the world the customer lives in, which is why it has to be read rather than bought.

Obesity and metabolic dysfunction were not new problems when GLP-1 arrived. The prevalence was known, the comorbidities documented, the failure of existing interventions well established. The cycle of effort, relapse, self-blame, and resignation had been internalized by millions of patients as an expected feature of their condition. The need was not hidden. It was hiding in plain sight, normalized by a healthcare system that had, in effect, decided the problem was the patient's responsibility. What changed was not the need. What changed was the context surrounding it: a world increasingly shaped by wellness culture, longevity ambition, and a shifting narrative reframing obesity from moral failure to metabolic condition. The stigma had not disappeared, but the permission structure was changing. Then the science became credible enough to generate genuine belief. The category did not need to be built from scratch. It needed to be unlocked, and any commercial model reading only behavior missed that distinction entirely, because the distinction lives in context.

What Pharma Built in the Name of Customer-Centricity

Customer-centricity has been pharma's declared ambition for more than two decades, and the aspiration is genuine. The problem is not the aspiration. The problem is what was built in its name. Most pharma companies have built commercial research capability: segmentation, message testing, channel preference analysis, journey mapping, prescriber profiling, patient behavior modeling. These are tools for understanding customers well enough to execute more effectively within a category that already exists. They are useful and necessary. They are not customer-centricity in any meaningful sense. They are commercial research in service of existing commercial objectives, relabeled as something more ambitious than they actually are.

The distinction explains why two decades of declared investment in customer-centricity did not, on its own, put most of the industry in a position to see obesity forming as a category. Commercial research is oriented toward behavior within a known frame. It asks what customers do, what they respond to, what channels they prefer. It is designed to optimize execution. It is not designed to detect the accumulation of unmet human burden before it declares itself as a market.

Dimension	Commercial Research	Customer Consciousness
Primary question	How do we execute more effectively?	What world does the customer inhabit?
Starting point	Product, category, or existing journey	Human context and unresolved burden
Core capability	Behavioral analysis and message optimization	Market sensing and context interpretation
Strategic output	Better execution within a known category	Recognition of categories before they form
Data orientation	What customers do and respond to	What customers are living with and trying to resolve
GLP-1 read	Optimize the GLP-1 customer journey	Understand why GLP-1 was inevitable

Dimension	Commercial Research	Customer Consciousness
Value to the enterprise	Incremental commercial performance	Pre-category market intelligence

◆ **PRACTICE PRISM** *Seeing the same reality through a different lens*

CONVENTIONAL LENS

Pharma has invested two decades building customer-centricity: segmentation, personalization, journey mapping, omnichannel engagement. These capabilities make the organization more effective at serving customers in markets it already occupies.

▶️ **THROUGH THE PRACTICE PRISM**

What pharma built is commercial research sophistication, not customer-centricity. Customer consciousness is what genuine customer-centricity produces when customer context is treated as a first principle: the capacity to see what the customer's world is making them need before the market has formed around it.

SECTION 3

Customer Consciousness as a Commercial Discipline

Customer Consciousness	The deep search, disciplined examination, and organizational internalization of customer context, grounded in a real regard for what people are living through. It is the operating discipline of customer context as a first principle: the capacity to see not just what customers do, but what their world is making them need, before the market has fully formed around it.

Those three words are not synonyms arranged for rhythm. They are three depths of organizational capability, and only the third is rare. **Search** is sensing: going where the burden lives, which is seldom where the data is convenient, into patient communities, caregiver forums, cash-pay behavior, and the language people use about their own lives. Most organizations can buy this. **Examination** is interpretation: converting what was heard into a structured read of the human condition, distinguishing a complaint from a burden, a preference from a need, a workaround from a demand signal. Some organizations can do this. **Internalization** is the depth almost no one reaches. It is the point at which customer context changes portfolio priorities, budget lines, commercial architecture, and organizational structure, not merely a deck. The test is auditable and unforgiving: name what changed structurally because of what you heard. In most organizations the honest answer is nothing, and the silence is the finding.

Empathy belongs in this definition, and it belongs precisely where it is placed: underneath the discipline as its ethic, never on top of it as its method. Novo Nordisk and Lilly did not out-feel the industry. They read a context correctly and built systems around it. Empathy that stops at feeling is sentiment, and sentiment has never in the history of this industry moved a portfolio decision. Empathy that is instrumented, that becomes search and examination and finally internalization, is foresight. That distinction is the difference between a values statement and a commercial capability, and it is the reason customer consciousness can be held to a standard, which is what separates a capability from a value.

The Replication Protocol

If GLP-1 is a masterclass, the point of a masterclass is that the technique transfers. What follows is the transferable technique: five practices presented in the order they are run, not as a menu of capabilities. The sequence matters. Burden listening establishes what people are carrying. Normalization auditing identifies which parts of that burden the system has decided are ordinary, which is where latent demand hides. Context mapping reconstructs the world that makes the burden mean what it means. Pre-category signal reading tests whether that world is already mobilizing commercially. Value realization assessment determines where a credible answer would have to perform to be believed.

Run in order, the protocol converts lived human experience into a category thesis. Run out of order, or run only partially, it produces the same customer research the industry already has.

Practice (in sequence)	What It Does
1. Burden Listening	Systematic scanning of what customers are carrying, not what they are buying. Patient communities, caregiver forums, and social listening calibrated to frustration, workaround behavior, and normalized resignation, which brand sentiment tracking never surfaces. The question is not what customers say about your product. It is what they say about their lives.
2. Normalization Auditing	Deliberately examining what the healthcare system has decided is ordinary that patients experience as unacceptable. This is the discipline of finding the GLP-1 pattern before the science arrives: identifying where clinical underservice, cultural stigma, or structural inadequacy has suppressed visible demand without reducing actual need. Where normalization is deepest, latent demand is largest.
3. Context Mapping	Understanding the full world the customer inhabits: the lifestyle pressures, cultural narratives, identity stakes, social dynamics, and economic realities that shape how they experience a condition and what solutions they will seek, accept, or reject. Context mapping produces understanding that cannot be generated from claims data or survey responses.
4. Pre-Category Signal Reading	Tracking the indicators that a human condition is approaching commercial inevitability before a formal category exists: off-label demand, direct-to-consumer spending, employer benefit shifts, consumer search behavior, startup formation in adjacent spaces, and influencer discourse. The category becomes visible in culture before it becomes visible in pipeline planning.
5. Value Realization Assessment	Mapping the full system through which a customer realizes the value a therapy promises, from diagnosis and access through onboarding, adherence, behavior change, and long-term identity integration. Where the gap between clinical outcome and lived experience is largest is where consumer-grade architecture investment produces the highest competitive return. This is the practice that joins the upstream reading to downstream value realization.

> ***The test of customer consciousness is auditable and unforgiving. Name what changed structurally because of what you heard. In most organizations the honest answer is nothing, and the silence is the finding.***

SECTION 4

The Anatomy of Inevitability

GLP-1 became inevitable because seven conditions converged simultaneously. This is the anatomy of a high-velocity category, and it is a repeatable pattern. Each condition can be assessed independently. When they converge, the signal is strong. When all seven align, the category is not a question of whether but when. The Convergence Readiness Model is the diagnostic instrument of customer consciousness: the mechanism by which customer context, held as a first principle, becomes legible to portfolio strategy, commercial architecture, and capital allocation.

Condition	Definition and the GLP-1 Read
1. Persistent Unresolved Need	The customer problem has endured for years or decades. It is not episodic. It is lived repeatedly, often after multiple failed attempts at resolution. In GLP-1: decades of inadequate clinical response to a condition affecting hundreds of millions globally.
2. Normalized Burden	The system has treated the pain as ordinary, personal failure, natural aging, or something the customer should simply manage. Normalization suppresses visible demand in conventional research. It does not reduce actual need. In GLP-1: obesity was systematically reframed as a willpower problem, obscuring the scale of latent demand.
3. Emotional and Identity Intensity	The condition affects how customers see themselves: confidence, identity, relationships, mobility, social belonging, and the sense of the future self. When a solution emerges it does not merely improve a biomarker. It changes a life. In GLP-1: body weight carries identity-level consequences no clinical measurement fully captures.
4. Cultural Readiness	The need is becoming more speakable, visible, and socially legitimate. Stigma is retreating. Employers, media, wellness culture, and social platforms are amplifying the issue. The permission structure is changing before the science arrives. In GLP-1: the reclassification of obesity from moral failure to metabolic condition changed what patients felt entitled to seek.
5. Patient Self-Recognition	Patients can identify their own condition without requiring a physician to name it first. Customers enter the commercial system already motivated, not as passive recipients of diagnosis. Self-recognition compresses the path from latent to activated demand and creates the conditions for direct-to-consumer access to compete with HCP-driven infrastructure. In GLP-1: nobody needed a doctor to tell them they had struggled with weight for years, which is precisely why Hims and Hers, Ro, and direct-to-consumer platforms captured position without prescriber-activation infrastructure.

Condition	Definition and the GLP-1 Read
6. Scientific or Technological Unlock	A credible new intervention creates genuine belief: not just clinical interest but patient and physician conviction that something meaningfully different is now possible. In GLP-1: the mechanism created belief at a scale prior interventions had never achieved.
7. Ecosystem Expansion Potential	The solution creates adjacent demand across food, fitness, care delivery, benefits, diagnostics, retail, or behavioral support. It stops being a product and starts being a platform. In GLP-1: adjacent markets in nutrition, muscle preservation, and behavioral support mobilized rapidly around the clinical breakthrough.

Why Agency Is the Central Variable

Across every condition where this pattern has produced a high-velocity category, the common denominator is not clinical severity or disease prevalence. It is agency. The customer need that GLP-1 addressed was not, at its core, weight loss. It was the restoration of control: over the body, over appetite, over health trajectory, over confidence, mobility, social participation, and the identity of the future self. Agency is a consumer-grade trait, and understanding why requires confronting an assumption that has shaped pharma commercial strategy for decades: the assumption that patients behave as patients.

The traditional model is built around a specific posture. The patient presents with a condition. The physician diagnoses and prescribes. The patient complies. The system is designed around clinical authority, not consumer choice. That model works adequately where the patient lacks the knowledge, the self-recognition, or the emotional urgency to act independently. It breaks down where all three are present. In conditions where self-recognition is high, where burden has been normalized by a system that chronically under-addressed it, and where identity stakes are significant, patients do not behave as patients. They behave as consumers. They research independently, often before speaking to a physician. They build workaround stacks of supplements, wellness protocols, and direct-to-consumer services. They spend their own money without waiting for coverage. They form communities, share protocols, and generate peer-to-peer evidence that influences adoption faster than clinical data can. They switch providers and products with the behavior of a consumer, not the compliance posture of a patient.

GLP-1 demonstrated this at category scale. Patients arrived at clinical encounters already informed, already motivated, and in many cases already self-directing access through telehealth platforms. The category mobilized employer benefit programs, consumer health platforms, and retail health infrastructure at a speed that physician-initiated categories rarely achieve, precisely because the patient was behaving as a consumer seeking agency, not a patient waiting for diagnosis.

This is why agency is not merely a psychological observation about what patients want. It is a structural variable that determines the shape of commercial competition in a category. A first principle that

determines the structure of competition belongs at the top of the reasoning chain, not the bottom of the launch plan.

> ***When patients seek agency, they behave as consumers. When they behave as consumers, the commercial system designed around physician-driven prescribing is no longer the only path to market. That is why Hims and Hers, Ro, and Amazon could compete in GLP-1 without traditional pharma infrastructure.***

◆ **PRACTICE PRISM** *Seeing the same reality through a different lens*

CONVENTIONAL LENS

Patients are clinical recipients. They receive diagnoses, accept prescriptions, and comply with treatment protocols designed around physician judgment. The commercial system is built to activate prescribers, not to serve consumers.

▶️ THROUGH THE PRACTICE PRISM

In high-burden, self-recognized, emotionally intense conditions, patients behave as consumers. The infrastructure built around prescriber activation is no longer the only path to market, and in high-agency categories it is increasingly not the primary one.

SECTION 5

Context Debt

There is a name for what accumulates in these conditions, and naming it correctly changes how a commercial organization behaves. Call it **context debt**: the liability an organization carries for customer context it has encountered but never internalized. Context debt is created the moment a burden is heard and filed instead of acted on. It compounds quietly, because normalization suppresses the visible signal without reducing the underlying need, which means the debt grows precisely where the reporting says nothing is wrong. It is not paid down by research. Research is how the debt is measured. Internalization is how it is retired.

Context Debt	The liability an organization carries for customer context it has encountered but never internalized. It is the upstream, pre-category counterpart to Commercial Value at Risk, the measure of value an enterprise is losing inside a category it already competes in. Where that figure counts what is leaking out of a market you are in, context debt counts what you will never collect from a market you did not see forming.

The proof of context debt is never financial. It is behavioral, and it is legible to anyone practicing burden listening. It appears in the language people use about themselves when they describe a condition, particularly the vocabulary of self-blame that signals a system has successfully transferred responsibility onto the patient. It appears in protocol-sharing inside patient communities, where people teach each other what the clinical encounter did not give them. It appears in cash-pay behavior, which is the purest expression of urgency because it is money spent without permission, coverage, or clinical validation. It appears in the quiet exit, the patient who stops raising the issue at appointments because raising it has stopped producing anything. Each of these is a receipt. Together they form the ledger, and the ledger is readable years before any market model registers a category.



Figure 1. Context debt accumulates wherever burden is heard and never internalized. Normalization suppresses the visible signal without reducing the need, so the debt grows precisely where the reporting says nothing is wrong.

This reframes what a supercycle is. A supercycle is not demand creation. It is context debt discharging, and the discharge pays out to whoever built the system positioned to receive it. Obesity's ledger has now been settled, and the largest share went to the two companies that had read the context and built for it first. A further share went to compounding pharmacies, telehealth platforms, and consumer health companies who had designed for the customer's experience of the therapy. The instructive point is that in both cases the payout followed the reading. Nine further ledgers remain open, and they are readable now.

The evidence that context debt is accumulating elsewhere at scale is already public and already priced. The global wellness market has been sized at over two trillion dollars. The global dietary supplement market exceeded $180 billion in 2023 and is projected to surpass $300 billion by the early 2030s. Compounded and bioidentical hormone therapy, marketed with claims about hormonal optimization and symptom relief, represents billions in annual spend directed at conditions the clinical system has chronically underserved. The women purchasing those products are not confused consumers. They are patients with genuine conditions who have been failed by a system that minimized their symptoms, and they are behaving as consumers because of it.

> ***The workaround economy is not a sign of market immaturity. It is the most powerful demand signal available and the most honest audit of unread customer context in existence. That spending does not forecast a market. It receipts a burden that was heard and never internalized.***

◆ **PRACTICE PRISM** *Seeing the same reality through a different lens*

CONVENTIONAL LENS

Consumer health, supplements, and wellness platforms are adjacent markets, not competitive threats. Pharma competes against other pharma companies for clinical credibility, prescriber access, and payer coverage.

THROUGH THE PRACTICE PRISM

The relevant competitors are already in market: supplement brands, wellness platforms, compounded pharmacies, and direct-to-consumer health companies capturing consumer spend in the absence of credible clinical alternatives. When pharma arrives with validated therapies, it is not entering a market. It is completing one that consumers have already built.

This is pharma's structural advantage. Not to compete with the supplement industry on its own terms, but to do what pharma uniquely can: bring scientifically validated, regulatory-approved, clinically credible interventions to conditions where consumer demand has already been established but where available solutions do not meet the standard that patients, payers, and healthcare systems ultimately require. Pharma does not need to create demand in these categories. Consumers have already created it. Pharma's opportunity is to legitimize it, scale it, and deliver against it with proof no wellness brand can match.

SECTION 6

Where the Pattern Is Already Forming

The Convergence Readiness Model does not exist to explain GLP-1 after the fact. It is a prospective tool for identifying what comes next. The conditions that made GLP-1 inevitable are not unique to obesity. They are present, in varying degrees of convergence, across a range of human conditions where persistent burden, emotional intensity, system failure, cultural readiness, patient self-recognition, and emerging scientific unlock are already aligning.

The assessment that follows applies the seven conditions to nine candidate conditions. The CRM signal reflects the degree of convergence currently visible, not a prediction of timing or mechanism, but a reading of the customer context that traditional commercial strategy is not designed to see. Self-recognition carries disproportionate weight in the reading, because conditions where patients identify their own burden without a clinical diagnosis mobilize faster once an unlock arrives, and are far more accessible to entrants who never built prescriber infrastructure at all.

THE NINE-CONDITION FORWARD ASSESSMENT

Convergence readiness across the seven conditions. Darker signals stronger convergence.

	Need Depth	Emotional Intensity	System Failure	Cultural Readiness	Self-Recognition	Scientific Unlock	CRM SIGNAL
Longevity and Healthspan	High	High	Moderate	High	High	Building	STRONG
Women's Hormonal Health	High	High	High	Shifting	High	Advancing	STRONG
Chronic Pain and Mobility	High	High	High	Moderate	High	Advancing	STRONG
Fertility and Reproductive	High	High	High	Shifting	High	Advancing	STRONG
Mental Health and Performance	High	High	Moderate	High	Moderate	Advancing	STRONG
Sleep and Nervous System	High	High	High	High	High	Fragmented	EMERGING
Metabolic Nutrition	High	Moderate	Moderate	High	High	Active	EMERGING
Cognitive Health and Focus	High	High	Moderate	High	Moderate	Building	EMERGING
Caregiving Infrastructure	High	High	High	Low	Low	Early	WATCH

High convergence · Moderate or in transition · Low convergence

Figure 2. The nine-condition forward assessment. Convergence readiness across the seven CRM conditions, with the resulting signal at right.



Figure 3. The nine conditions plotted against the CRM output grid, with GLP-1 at its 2021 position for reference. Quadrant position, not total score, is the strategic input.

Five Conditions in Depth

Nine conditions do not each warrant equal treatment. Five are worked below, chosen because each illustrates a structurally different shape the pattern takes. Two are conditions where burden has reached its ceiling and only the unlock is missing. One is a condition where consumers have already deployed capital at scale ahead of the clinical infrastructure. One is a condition where the ecosystem, not the burden, is doing the work. One is held back by a single variable that has nothing to do with the science. Together they show that a strong CRM signal does not mean the same thing in every condition, and that the commercial response has to be read from the shape of the convergence rather than from the strength of the headline.

Longevity and Healthspan

CRM SIGNAL **STRONG** GRID POSITION **Build Position**

Longevity and healthspan is the clearest structural parallel to pre-unlock obesity in the entire assessment, and the one where consumers have moved furthest ahead of the clinical system. Customers are not seeking simply to live longer. They are seeking to remain capable, independent, cognitively sharp, mobile, and socially relevant for longer, which makes the emotional and identity dimensions unusually high. Cultural readiness is already substantial: people are spending proactively on diagnostics, supplements, optimization protocols, and behavioral programs, not because medicine directed them to but because the desire for agency over aging is running ahead of the infrastructure. Scientific credibility is building across biomarkers, metabolic optimization, cellular aging, and personalized healthspan programming. The category is not yet formed. The conditions for it are advanced.

CUSTOMER EXCELLENCE IMPLICATION

This is the condition where the workaround economy is largest and the clinical answer is furthest behind it. Consumers have already priced the need and are funding it themselves, which means the demand does not have to be created and the relationships do not have to be bought at declaration prices. The first credible, systematic, regulatory-grade intervention will not be entering a market. It will be legitimizing one that consumers built.

Women's Hormonal Health

CRM SIGNAL **STRONG** GRID POSITION **Build Position**

Women's hormonal health, spanning menopause, perimenopause, PCOS, endometriosis, postpartum health, pelvic health, and sexual health, is one of the most consequential examples of normalized clinical neglect in modern medicine. The burden is not niche. It is population-scale, affecting every woman who ages, and the system has treated it for generations as something to be endured. The emotional and identity dimensions are significant: these are life transitions that affect confidence, continuity, functioning, intimacy, work, and sense of self. Cultural silence is breaking. The commercial infrastructure has barely begun to design around the actual human experience.

CUSTOMER EXCELLENCE IMPLICATION

Burden convergence is at or near maximum across persistence, normalization, emotional intensity, and self-recognition, with cultural readiness advancing rapidly. Unlock readiness is the only constrained dimension. That is the textbook Build Position: establish customer relationships, experience architecture, and category credibility now, so the unlock arrives into a market someone has already shaped.

Chronic Pain and Mobility

CRM SIGNAL **STRONG** GRID POSITION **Build Position**

Chronic pain and mobility carries a burden profile close to obesity's and a demand profile that behaves very differently. Tens of millions of patients have normalized a level of daily physical limitation that medicine has repeatedly failed to address, and the opioid crisis created a treatment gap that has never closed. The emotional and identity consequences of mobility loss run through independence, work, relationships, and social participation. Self-recognition is close to universal; nobody needs a clinician to tell them they are in pain. Scientific advances in neuromodulation, pain mechanism targeting, and behavioral integration are creating the conditions for a credible unlock.

CUSTOMER EXCELLENCE IMPLICATION

This condition shows that high self-recognition does not automatically produce activated demand. Stigma, and the resignation that follows years of being offered nothing acceptable, suppress the signal that conventional research would pick up. The commercial implication is specific: demand here will not be found by asking, it has to be read from behavior, and a credible non-addictive mechanism will meet unusually low switching resistance when it arrives.

Metabolic Nutrition

CRM SIGNAL **EMERGING** GRID POSITION **Act Now**

Metabolic nutrition is the most immediate adjacency in the assessment, and the only one where the unlock has already occurred. It happened inside GLP-1 itself. Patients on therapy are self-directing nutritional decisions around muscle preservation, protein intake, and metabolic identity, creating adjacent infrastructure demand that the primary category activated but never served. Unlike the other eight conditions, this one is not waiting on science. It is waiting on someone to build the system.

CUSTOMER EXCELLENCE IMPLICATION

The ecosystem expansion dimension, not the burden dimension, is doing the work here. That inverts the usual posture: the opportunity is immediate, and waiting carries a measurable cost inside the current fiscal year, not at some future unlock.

Caregiving Infrastructure

CRM SIGNAL **WATCH** GRID POSITION **Monitor**

Caregiving and aging-at-home infrastructure addresses one of the most emotionally intense and systemically unsupported customer contexts in healthcare. The customer is often not the patient. It is the adult child managing a parent's cognitive decline, the spouse coordinating care across multiple providers, the family navigating benefits, transportation, home safety, and end-of-life decisions with almost no coordinated support. The burden is persistent, expensive, and fragmented, and the scale of need is enormous.

CUSTOMER EXCELLENCE IMPLICATION

Every dimension scores high except one, and that one is decisive. Self-recognition is low: caregiver burden is intensely experienced but not yet legible to the person carrying it as an addressable need, which is to say as something other than a duty. That single variable, not the science and not the market size, is what holds this condition in Monitor. It also makes caregiving the clearest illustration of why self-recognition deserves disproportionate weight in the model.

SECTION 7

Running the Protocol

A masterclass that is only described has taught nothing. What follows runs the five-practice protocol end to end on a single condition, women's hormonal health, chosen because it carries the closest structural resemblance to pre-unlock obesity of any condition in the assessment. The purpose is not to advance a therapeutic claim. It is to demonstrate that the pattern that made GLP-1 legible in hindsight is legible in foresight when the protocol is actually run.

Practice	What It Surfaces in Women's Hormonal Health
1. Burden Listening	The vocabulary is the finding. Women describe perimenopause and related conditions in the language of self-management and self-blame: coping, pushing through, being told it is normal, being told it is stress, being told to wait. Community forums are dense with protocol-sharing, which is what people do when the clinical encounter has stopped producing answers. The recurring emotional register is not discomfort. It is the experience of not being believed, which is a materially different burden and a materially different design brief.
2. Normalization Auditing	The system has coded a population-scale physiological transition as an ordinary life stage to be endured instead of a treatable condition requiring care. That coding is reinforced by a generational treatment retreat following contested trial interpretation, by minimal clinical training time devoted to the transition, and by symptom presentations routinely attributed to stress, aging, or mood. Normalization here is close to maximum, which under the model means latent demand is close to maximum and visible demand in conventional research will systematically understate it.
3. Context Mapping	The condition arrives at the point of maximum external load: career seniority, adolescent or adult children, aging parents, and financial responsibility converging simultaneously. The stakes are identity-level, not symptomatic, touching confidence, cognitive reliability, professional standing, intimacy, and the sense of continuity with a prior self. The cultural narrative is shifting fast, from private endurance toward public discourse, employer benefit design, and open advocacy. That is the same permission-structure movement that preceded the obesity reframe, at an earlier point on the same curve.
4. Pre-Category Signal Reading	Every leading indicator is already firing. A compounded and bioidentical hormone market operating at billions in annual spend outside the standard of regulatory rigor. Direct-to-consumer platforms forming specifically around this transition. Employer benefits beginning to name it explicitly. Supplement formulations marketed directly at its symptom set. Startup formation across diagnostics, telehealth, and coaching. Consumers are not waiting, which is the single most reliable signal available that a category is genuinely forming.

Practice	What It Surfaces in Women's Hormonal Health
5. Value Realization Assessment	The gap between what a validated intervention could promise and what a woman would actually experience is enormous, and almost none of it is molecular. It sits in recognition and diagnosis, in prescriber confidence and willingness, in the design of the first conversation, in titration and expectation setting, in continuity across a transition measured in years, and in evidence that persuades a payer who has never been asked to fund this population at scale. That gap is the design brief, and it is where a commercial system, not an asset, decides the outcome.

Read together, the protocol produces a specific and actionable thesis. It also produces something the conventional sequence never generates: a design brief written before the asset exists. The same protocol, run against sleep, chronic pain, fertility, cognitive health, caregiving, longevity, mental health, and metabolic nutrition, produces eight further theses of the same structure and different content. That is what replication means here. Not a prediction that any one of these becomes the next GLP-1, but a repeatable method for reading customer context deeply enough that the question stops being a guess.

> ***The organizations that can run this protocol will be positioned in three or four of these conditions before the categories declare themselves. The organizations that cannot will read about the convergence in a competitor's pipeline announcement and call it a surprise, exactly as they did last time.***

SECTION 8

Customer Excellence: The Fourth Pillar

Everything argued to this point converges on a structural conclusion. If customer context is a first principle of commercial strategy, then it cannot live inside a program, a function, or a center of excellence bolted onto the existing model. First principles are institutional. They require a pillar.

Pharma commercial excellence was constructed on three pillars, professionalized over four decades. **Launch excellence** is the machinery of category entry, from launch sequencing and evidence packaging through pricing, access strategy, and the payer negotiations that determine coverage at the moment of entry. **Marketing excellence** covers segmentation, positioning, message development, content supply chains, omnichannel orchestration, and the measurement apparatus that governs promotional investment. **Sales excellence** is the science of sizing, structuring, targeting, deploying, and enabling the field organization. Each has its own benchmarks, consultancies, conferences, and career paths. Together they represent one of the most sophisticated commercial apparatuses in any industry.

Four decades of refinement have not touched the one limit they hold in common. Every one of them works inside a category that someone has already established. Launch excellence executes entry into a category that has already been defined. Marketing excellence positions against a defined competitive set. Sales excellence deploys against a defined target universe. Each reads customer behavior with increasing precision, and none reads customer context at all. None can answer where categories come from, why they form when they form, why patients in high-agency conditions route around the entire apparatus, or whether the customer ever realizes the value the clinical data promised. None of this criticizes the pillars. It describes their scope.



Figure 4. The three incumbent pillars share a single boundary condition. The fourth removes it.

Customer Excellence is the Fourth Pillar: the enterprise discipline that institutionalizes customer context as a first principle and converts it into commercial advantage at three altitudes. Upstream, it operates as portfolio intelligence, with the Convergence Readiness Model reading human conditions before they become categories and feeding that reading into portfolio strategy, business development, and capital allocation. Midstream, it operates as commercial architecture: consumer-grade design of the full value system around the customer's experience of value realization. Downstream, it operates as the realization layer, the operating capability that governs whether clinical promise converts into lived outcome, and where the leakage between intent and impact is found, measured, and closed.

Altitude	What the Fourth Pillar Does	What It Changes
Upstream: Portfolio	Customer consciousness as formal commercial intelligence. The Convergence Readiness Model applied across therapeutic adjacencies to read burden convergence and unlock readiness before category formation.	Portfolio strategy gains a customer context dimension no clinical, regulatory, or financial framework provides. The organization sees markets forming instead of discovering them in competitor pipeline announcements.
Midstream: Architecture	Consumer-grade commercial architecture. The full value system designed around the customer's path to realized value instead of the company's product launch model.	The basis of competition shifts from molecule to system. Experience architecture becomes a designed asset, not an accidental byproduct of launch execution.

Altitude	What the Fourth Pillar Does	What It Changes
Downstream: Realization	The realization layer as an operating capability. Systematic detection and closure of the gaps where clinical promise leaks before it becomes lived outcome and demonstrated value.	Adherence, experience, and identity transition become moats. Payer conversations shift from list-price defense to realized-value evidence.

Why the Midstream Altitude Decides the Category

Consumer-grade pharma is not a customer experience program. It is a commercial architecture discipline: the practice of designing the full system around the customer's experience of value realization instead of the company's product launch model. In a category defined by a single dominant mechanism, it is also the primary source of defensible advantage available to any company that did not establish first-mover position.

GLP-1 illustrates why with unusual clarity. The molecule was necessary. It was not sufficient. The competitive system that determines whether a patient realizes the value the science promises extends across diagnosis, eligibility, prior authorization, coverage, affordability, prescribing confidence, supply reliability, onboarding, titration support, side-effect management, nutrition guidance, adherence infrastructure, behavioral support, identity transition, and payer value demonstration. Every one of those elements is a customer experience. Every one is also a commercial outcome driver. Crucially, none of them require first-mover status to execute well.

The most instructive proof did not come from traditional pharma at all. Hims and Hers built a direct-to-consumer architecture around the exact emotional and identity dimensions that make GLP-1 resonate: frictionless access, subscription simplicity, a brand voice calibrated to confidence and agency, and onboarding designed around the patient's emotional state instead of the prescriber's workflow. Ro built integrated programs combining access with coaching, nutrition support, and continuous engagement. Amazon addressed a different dimension of the same system: the access, affordability, and fulfillment friction that determines whether patients who want the therapy can stay on it. None of them had a superior molecule. All of them had a superior read of the customer.

What they collectively demonstrate is that the moat in a maturing category is not built primarily through clinical differentiation. A late entrant that masters onboarding, adherence, behavioral support, identity transition, and the full ecosystem of value realization at a depth the early leaders have not achieved is not competing on the same terrain as everyone else. It is constructing a defensible position on terrain the leaders left undefended. A red ocean in the molecule can coexist with a blue ocean in the experience.

From Red Ocean to Blue Ocean

Companies that understand customer context at sufficient depth do not merely avoid red oceans. They create blue oceans, and they do it by shifting the basis of competition in their own favor before competitors can see that the basis has moved. The mechanism is straightforward. When a company understands the human condition underneath a market before that market fully declares itself, it can design the commercial system, the value architecture, and the customer experience around needs that competitors have not yet recognized as needs. By the time the category becomes visible to everyone, that company has already built the infrastructure, established the relationships, and created the switching costs that define category leadership. The basis of competition has moved from molecule to system, from product to experience, from feature to meaning. Competitors entering the space find themselves on terrain someone else designed, around a customer understanding they do not yet hold.

This is what Novo Nordisk and Lilly each did, independently and at the same time. Neither simply launched a drug into a waiting market. They built commercial architectures around a human condition the system had normalized and patients had internalized as their own failure. The companies now entering the category are competing in a space whose terms were set by two first movers who each understood, early, what customers actually needed. That is the blue ocean dynamic, and the useful part is that it is reproducible, deliberately, by any organization that builds customer consciousness as a standing capability instead of discovering it after the fact.

One implication deserves to be stated without decoration. The Fourth Pillar is an enterprise capability, not a function renamed. It cannot be delegated to a customer experience team measuring satisfaction, because its remit spans portfolio strategy, commercial architecture, and operating model. It cannot be absorbed into insights, because its output is not research but strategic foresight and system design. It sits at the same altitude at which the other three pillars were institutionalized when the industry decided that launch, promotional investment, and field deployment were too consequential to leave to improvisation. Customer context has now demonstrated, at a scale of tens of billions of dollars, that it belongs in that company.

> ***The first three pillars of commercial excellence answer how to compete in a category that exists. The Fourth Pillar answers where categories come from and whether customers realize the value the science promises. An industry that just watched companies without a single molecule capture the experience layer of its defining category no longer gets to treat that second set of questions as optional.***

◆ PRACTICE PRISM *Seeing the same reality through a different lens*

CONVENTIONAL LENS

Commercial excellence means best-in-class launch, marketing, and sales capability. Improving commercial performance means maturing each pillar against benchmark.

▶️ THROUGH THE PRACTICE PRISM

The three pillars answer one question with increasing precision: how do we compete in a category that exists? Commercial excellence is incomplete by design, and GLP-1 exposed the missing pillar in public.

SECTION 9

From Diagnosis to Allocation

A diagnostic that stops at a quadrant has produced an opinion, not a decision. The practical claim of this paper is not that customer consciousness produces better insight. It is that customer consciousness produces better capital decisions, earlier, at lower cost, with a more defensible thesis behind them. That claim applies identically to the CCO allocating commercial budget, the CSO allocating portfolio and business development capacity, and the investor allocating external capital. The instrument differs. The logic does not.

The mechanism is an asymmetry in the price of position. Every commercial asset that matters in a category, meaning customer relationships, experience infrastructure, community credibility, data assets, category authority, and the right partnerships, is cheapest before the category declares itself and reprices fastest immediately after. Conventional allocation waits for the declaration, because conventional evidence standards require it: prevalence models, competitor pipeline signals, validated mechanism. By the time those arrive the price of position has inflated, and the remaining play is share capture against an incumbent who bought the same assets at a fraction of the cost. Customer consciousness moves the decision point earlier on that curve. It is, in the plainest terms available, an option-pricing advantage.

That reframes the case for the Fourth Pillar in the only terms a capital allocator ultimately accepts. The return on customer consciousness is not measured in insight quality or customer satisfaction. It is measured in the spread between what category position cost when you bought it and what it would have cost when everyone else could see the category. GLP-1 priced that spread publicly and enormously.

CRM OUTPUT GRID | STRATEGIC POSITION AND ALLOCATION POSTURE



Figure 5. The CRM output grid. Quadrant position determines what should be bought, at what intensity, and against what return mechanism.

Grid Position	Allocation Posture	Instruments	Capital Profile	What You Are Buying
Build Position (high burden, low unlock)	Deploy ahead of the category. This is the highest-return quadrant and the one conventional allocation systematically skips, because the evidence standard it requires has not yet arrived.	Customer relationships and community presence, experience infrastructure, adjacent service positions, early partnerships, data assets, category authority through evidence generation and advocacy.	Low absolute spend, multi-year horizon, staged against convergence movement, which moves on its own timetable.	An option on the unlock, at pre-declaration prices. The unlock arrives into a market you have already shaped.

Grid Position	Allocation Posture	Instruments	Capital Profile	What You Are Buying
Act Now (high burden, high unlock)	Design the full value system, not the asset. The category is forming or formed, so molecule competition is already priced and experience architecture is not.	Consumer-grade commercial architecture, onboarding and adherence systems, identity transition support, realized value evidence for payers, ecosystem and adjacency positions.	High intensity, compressed horizon, concentrated. Speed of system build is the binding constraint, not capital availability.	A moat on terrain the leaders left undefended. The experience layer is where late entrants can still win.
Proceed with Caution (low burden, high unlock)	Fund the context, not the launch. Science ahead of customer readiness is the most reliable predictor of an expensive commercial disappointment.	Cultural permission building, self-recognition development, diagnostic pathway and awareness infrastructure, patient and physician belief formation.	Moderate and patient. Underwrite the demand-side conditions with the same seriousness as the trial.	The customer readiness the science will otherwise arrive without. This is where launch excellence alone reliably fails.
Monitor (low burden, low unlock)	Hold. Instrument the condition without funding it, and reassess on movement in either axis.	Standing burden listening coverage, normalization audit refresh, pre-category signal tracking at low cost.	Minimal. The cost of watching is trivial against the cost of missing.	Optionality on a condition that is not yet investable but may become so quickly.

Two disciplines make this logic hold under scrutiny. The first is that burden convergence and unlock readiness must be scored separately and never summed into a single number, because the sum destroys exactly the information the allocation decision needs. A condition scoring at maximum on burden and minimum on unlock is a Build Position play; a condition with the identical total distributed evenly is not investable at all. The second is that self-recognition carries disproportionate weight, because it is the strongest available predictor of both adoption velocity and direct-to-consumer viability. High self-recognition means a category can mobilize without your commercial infrastructure, which is simultaneously the largest opportunity and the largest threat in this framework. GLP-1 demonstrated both faces of that variable within a single category, in the same eighteen months.

ON YOUR WHITEBOARD THE COMMERCIAL LEADERSHIP TEAM

1. Plot our two most important therapeutic adjacencies on the CRM output grid. Does our current capital deployment match the quadrant, or are we funding an Act Now play in a Build Position market and paying declaration prices for pre-declaration assets?

2. What proportion of our commercial capital is committed to categories that have already declared themselves? That proportion is the best single proxy available for whether we are buying position or buying share.

3. Where in our organization is customer burden being systematically read, not customer behavior, customer burden, and is that intelligence reaching portfolio decisions, or stopping at execution?

4. What is our commercial system designed around in our highest-priority category: the product launch model or the customer's full experience of value realization? Where is the gap largest, and what is it worth?

5. Can we name a portfolio or budget decision that changed because of what we heard from customers? Internalization is auditable. If the answer is nothing, we have context debt and no mechanism for retiring it.

6. If commercial excellence in our organization gained a fourth pillar tomorrow, with the same institutional standing as launch, marketing, and sales, what would it own on day one, and who would lead it?

> ***Every asset that matters in a category is cheapest before the category declares itself and reprices fastest immediately after. Customer consciousness moves the decision point to the left of that repricing. That is the whole commercial argument, and GLP-1 settled it in public.***

The Bottom Line

Every pharma boardroom is asking how to get into GLP-1. It is the wrong question, and not because the category is unattractive. It is the wrong question because it has already been answered by two companies who did the harder work first, and because answering it now means buying position in a market that has finished forming at prices set by the people who formed it.

The question worth the same executive hours is what comes next. GLP-1 is two things at once. It is the largest commercial supercycle in modern pharma, which capital markets can size precisely and explain not at all. It is also a demonstration that the human context underneath a category is readable years before the category exists, because Novo Nordisk and Lilly read it. The supercycle is what happened. The reading is why, and only the reading transfers.

What almost no organization has built is the organ that makes the reading repeatable. That absence is the real opportunity, because it means the capability is still available to whoever institutionalizes it first. Massive markets do not have to arrive as bolts of lightning, and treating them that way is a choice, not a condition of the industry. Categories have an anatomy, the anatomy can be scored, and a scored anatomy can be run on a cadence against an entire portfolio.

That anatomy is not unique to obesity. It is already forming in longevity, women's hormonal health, sleep, mental health, chronic pain, fertility, cognitive health, caregiving, and metabolic nutrition. The companies that read those convergences now, and design commercial systems around the human burden underneath them, will not be competing in the categories that follow. They will be defining them.

Customer consciousness is the discipline that makes that possible, and the Fourth Pillar is what makes the discipline permanent. Not a philosophy. Not a program. An enterprise capability with a first principle at its foundation, a diagnostic model at its core, a consumer-grade architecture standard in its build, and a direct line to portfolio strategy at its head. The industry institutionalized launch excellence, marketing excellence, and sales excellence when it decided those disciplines were too consequential to improvise. Customer context has now presented the same case, in public, at a scale no benchmark deck can obscure.

> ***The strategic question is not: how do we compete in GLP-1? It is: what did GLP-1 reveal about the human experience that a three-pillar commercial model was never built to see, and what will it cost to be missing the fourth pillar when the next convergence arrives?***

About the Author

Wayne Simmons, CCXP, is the Founder and Commercial Systems Architect of The Customer Excellence Agency, a pharma and life sciences commercial systems architecture firm. He is the author of *The Customer Excellence Enterprise* (Wiley), founding faculty in the MS in Customer Experience Management program at Michigan State University's Broad College of Business, and a former senior commercial and CX leader at Pfizer and Bayer. CEA works with global pharmaceutical and life sciences organizations to build the predisposition to unlock customer and experience-led growth, architecting the commercial systems that connect clinical value to realized customer and business outcomes.

About CEA Practice Papers

CEA Practice Papers set out the doctrine of the practice: first-party arguments, each carrying an instrument, written for senior commercial leaders and investors in pharma and life sciences. They are designed to inform decision-making at the intersection of commercial architecture, customer intelligence, and enterprise value creation. They do not constitute investment advice.

In This Collection	The Argument
The Pharma Front Door	Pharma's customer-facing architecture is organized around brands while customers experience one relationship. The correction is an AI-facilitated enterprise contact layer that preserves brand accountability while creating continuity across HCP and patient relationships.
Closing Pharma's Intent-to-Impact Gap	Commercial value leaks between what the enterprise intends and what the customer experiences. The Value Leakage Ladder instruments that leakage, and field intelligence and activation close it.
The GLP-1 Masterclass (this paper)	Customer context is a first principle of commercial strategy. The Convergence Readiness Model reads where categories are forming before they declare themselves, and Customer Excellence is the Fourth Pillar that institutionalizes the reading.

Sources and References

The following sources inform the market data, company references, and factual claims in this paper. The Convergence Readiness Model, the customer consciousness discipline, context debt, the Fourth Pillar framework, and the nine-condition assessment represent original CEA analysis and do not reflect the views of any cited organization.

IQVIA Institute for Human Data Science. The Global Use of Medicines 2025: Outlook to 2029. *IQVIA Institute, 2025.*

World Health Organization. Guideline for the Use of GLP-1 Receptor Agonist Medicines in the Treatment of Obesity. *Geneva: WHO, December 2025.*

Novo Nordisk A/S. Annual Report 2024. *Bagsvaerd: Novo Nordisk, 2025.*

Eli Lilly and Company. 2024 Annual Report to Shareholders. *Indianapolis: Eli Lilly, 2025.*

Hims and Hers Health, Inc. Annual Report on Form 10-K, Fiscal Year 2024. *San Francisco, 2025.*

Ro. Company overview and weight management program documentation. ro.co, 2025.

Amazon, Inc. Amazon Pharmacy and Amazon Clinic service documentation, 2025.

Cigna Group. Employee benefits coverage update communications, 2026; reported by Reuters, May 2026.

McKinsey and Company. The trends defining the global wellness market. *McKinsey Quarterly, 2021, with updated analyses published 2023 and 2024.*

Grand View Research. Dietary Supplements Market Size, Share and Trends Analysis Report, *2024.*

Endocrine Society position statements on compounded bioidentical hormones, and FDA communications on compounded drug oversight, 2023 to 2025.

Simmons, Wayne. The Customer Excellence Enterprise. *Hoboken: Wiley, 2023.*

CEA Analysis Note. Condition scoring reflects CEA's proprietary framework applied to publicly available market, cultural, and clinical evidence as of July 2026. Wellness market figures are directional estimates drawn from published third-party research and are intended to illustrate the scale of consumer demand in pre-category conditions, not to constitute precise market sizing.